Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Metabolomics of Anaphylaxis

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Aleena Banerji, Massachusetts General Hospital Identifier:
First received: August 7, 2012
Last updated: October 11, 2016
Last verified: October 2016

Metabolomics is the study of metabolic pathways and the unique biochemical molecules which result from the regulatory response to physiological stressors, disease processes, or drug therapy. By measuring changes in metabolite concentrations, the range of biochemical effects and therapeutic intervention can be determined.

Aspirin exacerbated respiratory disease (AERD) is a chronic inflammatory disease characterized by chronic rhinosinusitis, nasal polyposis, asthma, and airway reactivity to aspirin and/or other nonsteroidal anti-inflammatory drugs (NSAIDs). This reaction to aspirin during challenge/desensitization is equivalent to an allergic drug reaction however we are able to evaluate these specific reactions in a controlled, clinical environment. This population of patients undergoing aspirin desensitization is ideal for studying metabolomics as serial blood sampling can be performed in patients before, during a reaction, and after aspirin desensitization, thereby allowing each patient to serve as his or her own biological control. The investigator hopes that this study of metabolomics will allow for better methods of identifying anaphylaxis in the future.

Patients With AERD Undergoing Aspirin Desensitization

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: The Metabolomics of Anaphylaxis

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Change in metabolic profile of blood serum metabolites from Baseline to 1 week post-desensitization [ Time Frame: before start of aspirin desensitization, 2 hours into desensitization, at time of reaction(s) - an expected average of 6 hours into desensitization, 1 week post-desensitization ] [ Designated as safety issue: No ]
    Metabolic profiling will be done on specific blood serum metabolites including lipid mediators, amino acids, and leukotrienes.

Biospecimen Retention:   Samples With DNA
We retain and freeze the plasma from blood after spinning down whole-blood samples.

Estimated Enrollment: 12
Study Start Date: March 2012
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Aspirin desensitization
This group of patients has AERD (aspirin exacerbated respiratory disease) and is undergoing aspirin desensitization.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients ages 18-75, history of an allergic reaction to aspirin and referred for a clinically indicated outpatient or inpatient aspirin desensitization procedure for aspirin exacerbated respiratory disease (AERD)

Inclusion Criteria:

  • Patients ages 18-75 with a history of aspirin anaphylaxis or a history of hypersensitivity reaction to aspirin and referred for a clinically indicated outpatient or inpatient aspirin desensitization procedure for AERD.

Exclusion Criteria:

  • Pregnancy/breastfeeding, possibility of poor compliance, unwilling to undergo aspirin desensitization.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01666275

United States, Massachusetts
Massachusetts General Hospital - Allergy Associates
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Principal Investigator: Aleena S Banerji, MD Massachusetts General Hospital
  More Information

Responsible Party: Aleena Banerji, MD, Assistant Professor of Medicine, Massachusetts General Hospital Identifier: NCT01666275     History of Changes
Other Study ID Numbers: 2012P000448 
Study First Received: August 7, 2012
Last Updated: October 11, 2016
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Hypersensitivity, Immediate
Immune System Diseases processed this record on October 25, 2016